

Tivantinib

Catalog No: tcsc0030



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Size: 500mg



Specifications

CAS No:

905854-02-6

Formula:

$C_{23}H_{19}N_3O_2$

Pathway:

Protein Tyrosine Kinase/RTK

Target:

c-Met/HGFR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (270.69 mM)

Alternative Names:

ARQ 197

Observed Molecular Weight:

369.42


Product Description

Tivantinib is a novel and highly selective **c-Met** tyrosine kinase inhibitor with **K_i** of 355 nM.

IC50 & Target: Ki: 355 nM (c-Met)^[1]

In Vitro: Tivantinib (ARQ 197) selectively inhibits c-Met activity in cell-free and cell-based assays. c-Met-expressing cancer cell lines treated with Tivantinib display either a dose-dependent loss of proliferative capacity or caspase-dependent apoptosis that positively correlates with either ligand-dependent c-Met activity or constitutively active c-Met. To examine the biochemical mode of inhibition of Tivantinib, kinetic analyses are done using recombinant human c-Met in a filtermat-based assay. The K_m of ATP is $50.5 \pm 2.2 \mu\text{M}$, which is similar to the K_m value of ATP. In these kinetic studies, Tivantinib inhibits human recombinant c-Met with a calculated inhibitory constant (K_i) of $\sim 355 \text{ nM}$. In vitro exposure to Tivantinib inhibits constitutive c-Met phosphorylation in HT29 and MKN-45 cells, and HGF-induced c-Met phosphorylation in MDA-MB-231 and NCI-H441 cells with an IC_{50} of 100 to 300 nM^[1]. Tivantinib is a low-molecular-weight compound, and is the first in class orally available selective inhibitor of c-Met^[2].

In Vivo: Pharmacodynamically, the phosphorylation of c-Met in human colon xenograft tumors (HT29) is strongly inhibited by Tivantinib (ARQ 197), as assessed by a dramatic reduction of c-Met autophosphorylation 24 hours after a single oral dose of 200 mg/kg of Tivantinib. This same dosage in mice shows that tumor xenografts are exposed to sustained plasma levels of Tivantinib, consistent with the observed pharmacodynamic inhibition of c-Met phosphorylation and inhibition of proliferation of c-Met harboring cancer cell lines. A C_{max} of 5.73 $\mu\text{g/mL}$ (13 μM), an area under the concentration-time curve of 12.1 $\mu\text{g/mL h}$, and a $t_{1/2}$ of 2.4 hours are measured. Plasma levels of Tivantinib 10 hours after dosing are determined to be 1.3 μM , >3-fold above the biochemical inhibitory constant of Tivantinib for c-Met^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!